The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
6-(1H-pyrazolo[4,3-b]pyridin-3-ylamino)-2-(cyclobutylmethyl)isoquinolin-1(2H)-one ID: ALA4755785
PubChem CID: 162655927
Max Phase: Preclinical
Molecular Formula: C20H19N5O
Molecular Weight: 345.41
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: O=c1c2ccc(Nc3n[nH]c4cccnc34)cc2ccn1CC1CCC1
Standard InChI: InChI=1S/C20H19N5O/c26-20-16-7-6-15(22-19-18-17(23-24-19)5-2-9-21-18)11-14(16)8-10-25(20)12-13-3-1-4-13/h2,5-11,13H,1,3-4,12H2,(H2,22,23,24)
Standard InChI Key: FDTKFKAGUXSNQG-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 30 0 0 0 0 0 0 0 0999 V2000
41.0686 -2.8354 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.0675 -3.6549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7755 -4.0639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.7737 -2.4265 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.4824 -2.8318 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.4831 -3.6508 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.1917 -4.0578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.8999 -3.6470 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.8952 -2.8249 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
43.1861 -2.4215 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.3595 -4.0629 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
39.6521 -3.6538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.5662 -2.8431 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
38.7670 -2.6726 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
38.9042 -3.9877 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.3603 -3.3800 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.5642 -3.5478 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.3108 -4.3227 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.8597 -4.9300 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.6538 -4.7591 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
43.1817 -1.6044 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.6004 -2.4120 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.3106 -2.8163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.5256 -3.6076 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
46.3137 -3.3913 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
46.0974 -2.6033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 1 0
10 5 1 0
2 11 1 0
11 12 1 0
12 13 2 0
13 14 1 0
14 16 1 0
15 12 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 15 1 0
10 21 2 0
9 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
25 26 1 0
26 23 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 345.41Molecular Weight (Monoisotopic): 345.1590AlogP: 3.82#Rotatable Bonds: 4Polar Surface Area: 75.60Molecular Species: NEUTRALHBA: 5HBD: 2#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 12.88CX Basic pKa: 2.56CX LogP: 3.30CX LogD: 3.30Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.59Np Likeness Score: -1.29
References 1. Panarese JD,Engers DW,Wu YJ,Guernon JM,Chun A,Gregro AR,Bender AM,Capstick RA,Wieting JM,Bronson JJ,Macor JE,Westphal R,Soars M,Engers JE,Felts AS,Rodriguez AL,Emmitte KA,Jones CK,Blobaum AL,Conn PJ,Niswender CM,Hopkins CR,Lindsley CW. (2019) The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate., 29 (2.0): [PMID:30503632 ] [10.1016/j.bmcl.2018.10.050 ]